Name (Synonyms) | Correlation | |
---|---|---|
drug1325 | Hydroxychloroquine, Azithromycin Wiki | 1.00 |
drug761 | Convalescent Serum Wiki | 1.00 |
drug1329 | Hydroxychloroquine, Doxycycline Wiki | 1.00 |
drug1326 | Hydroxychloroquine, Clindamycin Wiki | 1.00 |
drug1438 | Interferon-Alpha2B Wiki | 1.00 |
drug1328 | Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki | 1.00 |
drug1327 | Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki | 1.00 |
drug1607 | Losartan Wiki | 0.35 |
drug1743 | Methylprednisolone Wiki | 0.28 |
drug2413 | Remdesivir Wiki | 0.23 |
drug2928 | Tocilizumab Wiki | 0.17 |
Name (Synonyms) | Correlation | |
---|---|---|
D009202 | Cardiomyopathies NIH | 0.58 |
D002318 | Cardiovascular Diseases NIH | 0.19 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001638 | Cardiomyopathy HPO | 0.58 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.19 |
There is one clinical trial.
COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.
Description: T-cell immunophenotype
Measure: T-cell immunophenotype Time: 12 months from enrollmentDescription: death, survival to discharge
Measure: Mortality Time: 12 months from enrolmentDescription: Admission to the intensive care
Measure: ITU admission Time: 12 months from enrolmentDescription: Defined by troponin rise to >99th centile
Measure: Myocardial injury Time: 12 months from enrolment